Filing Details
- Accession Number:
- 0001209191-18-003469
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-12 18:15:00
- Reporting Period:
- 2018-01-10
- Accepted Time:
- 2018-01-12 18:15:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Pharmaceuticals Inc. | PCRX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1204788 | M David Stack | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Ceo And Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-10 | 28,885 | $1.61 | 129,331 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-01-10 | 23,372 | $39.96 | 105,959 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-01-10 | 4,628 | $41.03 | 101,331 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-01-10 | 885 | $41.97 | 100,446 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2018-01-10 | 28,885 | $0.00 | 28,885 | $1.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
83,190 | 2020-09-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 18,596 | Indirect | By Stack Schroon Mohawk FLP |
Common Stock | 1,208 | Indirect | By LCK Investment LLC |
Footnotes
- The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- Includes 167 shares of common stock acquired under the issuer's employee stock purchase plan in December 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.625 to $40.60, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.55, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.70 to $42.25, inclusive.
- Mr. Stack is the general partner of Stack Schroon Mohawk FLP. Mr. Stack and his wife are the owners of LCK Investment LLC.
- The option vested as to 50% of the option shares on February 2, 2011, 19,378 option shares vested on February 3, 2011, and the remaining option shares vested in successive monthly installments for the subsequent 19 months.